CREATIVE MEDICAL TECHNOLOGY (CELZ) Stock Fundamental Analysis
USA - NASDAQ:CELZ - US22529Y4089 - Common Stock
3.02 USD
-0.03 (-0.98%)
CELZ gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CELZ as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, CELZ is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CELZ has reported negative net income.
CELZ had a negative operating cash flow in the past year.
CELZ had negative earnings in 4 of the past 5 years.
In the past 5 years CELZ always reported negative operating cash flow.
1.2 Ratios
CELZ's Return On Assets of -81.15% is on the low side compared to the rest of the industry. CELZ is outperformed by 68.48% of its industry peers.
Looking at the Return On Equity, with a value of -84.45%, CELZ is in line with its industry, outperforming 51.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.15% | ||
| ROE | -84.45% | ||
| ROIC | N/A |
ROA(3y)-61.52%
ROA(5y)-1011.99%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CELZ has a better Gross Margin (60.00%) than 78.24% of its industry peers.
CELZ's Gross Margin has declined in the last couple of years.
CELZ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.52%
GM growth 5Y-3.2%
2. Health
2.1 Basic Checks
CELZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CELZ has been increased compared to 1 year ago.
Compared to 5 years ago, CELZ has more shares outstanding
There is no outstanding debt for CELZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 2.04 indicates that CELZ is not a great score, but indicates only limited risk for bankruptcy at the moment.
CELZ's Altman-Z score of 2.04 is fine compared to the rest of the industry. CELZ outperforms 68.29% of its industry peers.
CELZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.04 |
ROIC/WACCN/A
WACC8.78%
2.3 Liquidity
CELZ has a Current Ratio of 23.89. This indicates that CELZ is financially healthy and has no problem in meeting its short term obligations.
CELZ has a better Current ratio (23.89) than 96.62% of its industry peers.
A Quick Ratio of 23.89 indicates that CELZ has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 23.89, CELZ belongs to the best of the industry, outperforming 96.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 23.89 | ||
| Quick Ratio | 23.89 |
3. Growth
3.1 Past
CELZ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.48%, which is quite impressive.
The Revenue for CELZ has decreased by -71.43% in the past year. This is quite bad
Measured over the past years, CELZ shows a very negative growth in Revenue. The Revenue has been decreasing by -42.17% on average per year.
EPS 1Y (TTM)21.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.76%
Revenue 1Y (TTM)-71.43%
Revenue growth 3Y-50.37%
Revenue growth 5Y-42.17%
Sales Q2Q%-100%
3.2 Future
The Earnings Per Share is expected to grow by 29.08% on average over the next years. This is a very strong growth
Based on estimates for the next years, CELZ will show a very strong growth in Revenue. The Revenue will grow by 544.50% on average per year.
EPS Next Y17.52%
EPS Next 2Y10.29%
EPS Next 3Y37.54%
EPS Next 5Y29.08%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y1517.11%
Revenue Next 5Y544.5%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CELZ. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELZ. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CELZ's earnings are expected to grow with 37.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.29%
EPS Next 3Y37.54%
5. Dividend
5.1 Amount
CELZ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CELZ (11/18/2025, 12:12:25 PM)
3.02
-0.03 (-0.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.78%
Inst Owner Change-14.79%
Ins Owners0.49%
Ins Owner Change0%
Market Cap7.79M
Revenue(TTM)6.00K
Net Income(TTM)-5.77M
Analysts82.86
Price Target20.4 (575.5%)
Short Float %3.3%
Short Ratio0.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.59%
Min EPS beat(2)-56.49%
Max EPS beat(2)25.3%
EPS beat(4)2
Avg EPS beat(4)-22.99%
Min EPS beat(4)-74.29%
Max EPS beat(4)25.3%
EPS beat(8)3
Avg EPS beat(8)-12.91%
EPS beat(12)6
Avg EPS beat(12)-54.93%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)23.81%
EPS NQ rev (3m)23.81%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1298.6 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.14 | ||
| P/tB | 1.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.18
EYN/A
EPS(NY)-2.91
Fwd EYN/A
FCF(TTM)-2.2
FCFYN/A
OCF(TTM)-2.2
OCFYN/A
SpS0
BVpS2.65
TBVpS2.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.15% | ||
| ROE | -84.45% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60% | ||
| FCFM | N/A |
ROA(3y)-61.52%
ROA(5y)-1011.99%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.52%
GM growth 5Y-3.2%
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 23.89 | ||
| Quick Ratio | 23.89 | ||
| Altman-Z | 2.04 |
F-Score4
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.76%
EPS Next Y17.52%
EPS Next 2Y10.29%
EPS Next 3Y37.54%
EPS Next 5Y29.08%
Revenue 1Y (TTM)-71.43%
Revenue growth 3Y-50.37%
Revenue growth 5Y-42.17%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y1517.11%
Revenue Next 5Y544.5%
EBIT growth 1Y2.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.87%
OCF growth 3YN/A
OCF growth 5YN/A
CREATIVE MEDICAL TECHNOLOGY / CELZ FAQ
What is the ChartMill fundamental rating of CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
ChartMill assigns a fundamental rating of 4 / 10 to CELZ.
What is the valuation status of CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
ChartMill assigns a valuation rating of 1 / 10 to CREATIVE MEDICAL TECHNOLOGY (CELZ). This can be considered as Overvalued.
How profitable is CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
CREATIVE MEDICAL TECHNOLOGY (CELZ) has a profitability rating of 1 / 10.
What is the financial health of CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
The financial health rating of CREATIVE MEDICAL TECHNOLOGY (CELZ) is 8 / 10.
What is the earnings growth outlook for CREATIVE MEDICAL TECHNOLOGY?
The Earnings per Share (EPS) of CREATIVE MEDICAL TECHNOLOGY (CELZ) is expected to grow by 17.52% in the next year.